Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) reported Q1 loss of $0.98, $0.45 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.16 million.

Reiterates FY11 revs outlook.

Earnings Guidance